Dec. 19, 2024 - Despite a strong start to the year, activist activity in Canada in 2024 tapered to pre-pandemic levels. This reversion to more historic annual totals follows a notable resurgence of shareholder demands directed at Canadian public companies in 2023, when shareholder engagement reached its...
Announcement
Searchlight Pharma Inc. Sells to Apotex Inc.
Davies acted for the shareholders of Searchlight Pharma Inc. (Searchlight) in connection with the sale of their 100% interest to Apotex Inc. (Apotex).
Searchlight is a private, rapidly-growing Canadian company known for their innovative branded pharmaceuticals with a global reach that executes best-in-class search, acquisition, commercialization and focused development of innovative and unique specialty healthcare products.
With the deal now completed, Apotex is even better positioned for growth within the specialty branded pharmaceutical market, by adding Searchlight’s diverse portfolio of over 60 products and a full-service branded pharmaceutical platform, as well as Searchlight’s established business development networks in Canada and internationally.
The Davies team that advised on this transaction includes Hillel Rosen, Sébastien Roy, Shayna Goldman, Matthew Hendy, Noah Abitbol and Sergio Rodriguez (M&A); Brian Bloom and Taj Kudhail (Tax); Jim Dinning and Umang Khandelwal (Competition); Max Jarvie, Sumeet Dang and Benoit Archambault (IP/Privacy); Hélène Bussières and Arianna Yoffe (Employment); Marie-Claude Bellemare (Environment); Faiz Lalani (Dispute Resolution).
Related
Governance Insights: Nominee Directors – Fiduciary Obligations and the Limits of Information Sharing
Oct. 08, 2024 - The corporate life of a nominee director has been characterized as having the potential to be “neither happy nor long. ” In this Governance Insights article, we discuss the fundamental fiduciary considerations that nominee directors, nominating shareholders and companies should bear in...
